<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335581</url>
  </required_header>
  <id_info>
    <org_study_id>C69-10-M</org_study_id>
    <nct_id>NCT01335581</nct_id>
  </id_info>
  <brief_title>Study of Laser Treatment of Melasma</brief_title>
  <official_title>A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConBio, a Cynosure Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the RevLite laser in the treatment of refractory
      mixed type melasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Melasma Area Severity Assessment (MASI)</measure>
    <time_frame>3 Months</time_frame>
    <description>The severity of the melasma is assessed based on a photographic scale.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Refractory Mixed Type Melasma</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser treatment added to microdermabrasion and topical lightening agent regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-Switched Nd:YAG Laser (RevLite)</intervention_name>
    <description>Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fitzpatrick Skin Type III-VI

          -  mixed (epidermal and dermal) melasma diagnosed by Wood's Lamp exam

          -  age 18 or older

          -  melasma persisting for greater than 6 months that has failed to respond to
             conventional treatment with hydroquinone or other topical lightening agents

          -  written and verbal informed consent

          -  willing and able to comply with study instructions and return to the clinic for
             required visits

        Exclusion Criteria:

          -  Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant
             during the study

          -  history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins
             or photodermatosis

          -  any skin pathology or condition that could interfere with the evaluation or requires
             the use of interfering topical or systemic therapy

          -  uncorrected coagulation defect or is currently using anti-coagulation medication
             (including but not limited to heavy aspirin therapy)

          -  any condition which, in the investigator's opinion, would make it unsafe for the
             subject to participate in this research study

          -  currently enrolled in an investigational drug or device trial, or has received an
             investigational drug or has been treated with an investigational device within 30 days
             prior to entering this study

          -  inability to communicate or cooperate with the investigator due to language problems,
             poor mental development, or impaired cerebral function

          -  unreliability for the study (this includes subjects who engage in excessive alcohol
             intake or drug abuse, or subjects who are unable to return for scheduled follow-up
             visits)

          -  use of photosensitizing drugs within a timeframe where photosensitization from these
             drugs may still be present

          -  need to be exposed to artificial tanning devices or excessive sunlight during the
             trial

          -  Diabetes Type I or II

          -  sensitivity to hydroquinone or Retin-A

          -  evidence of a compromised immune system or hepatitis

          -  use of bleaching creams or retinoids within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arielle Kauvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Laser and Skin Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Laser and Skin Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

